Latest Kaiser Health News Stories
KHN, in collaboration with PBS NewsHour, reports on the skyrocketing cost of insulin — and the trend’s deadly consequences. The price in the U.S. nearly doubled from 2012 to 2016, prompting some patients and activists to travel to Canada, where insulin can be 90% cheaper.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
In California, people who are black or Latino are more than twice as likely as whites to undergo amputations related to diabetes, a Kaiser Health News analysis found. The pattern is not unique to California.
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
The Adelanto ICE Processing Center houses nearly 2,000 people in California. Federal, state and watchdog reviews say the Florida-based firm that runs the facility fails to provide adequate health care.
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life-or-death issue. Now a grass-roots movement is pushing for change.
Insurance companies profit from government contracts but are subject to little oversight of how they spend the money or care for patients. The expansion of Medicaid under the Affordable Care Act has only exacerbated the problem.
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.
In a major coup for the beverage industry, California lawmakers agreed to ban cities and counties from adopting soda taxes for the next 12 years. In exchange, the beverage industry agreed to pull an initiative off the November ballot that, if passed, would have made it much harder for local governments to raise taxes.